Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

British Journal of Pharmacology
T BisognoV Di Marzo

Abstract

1. (-)-Cannabidiol (CBD) is a non-psychotropic component of Cannabis with possible therapeutic use as an anti-inflammatory drug. Little is known on the possible molecular targets of this compound. We investigated whether CBD and some of its derivatives interact with vanilloid receptor type 1 (VR1), the receptor for capsaicin, or with proteins that inactivate the endogenous cannabinoid, anandamide (AEA). 2. CBD and its enantiomer, (+)-CBD, together with seven analogues, obtained by exchanging the C-7 methyl group of CBD with a hydroxy-methyl or a carboxyl function and/or the C-5' pentyl group with a di-methyl-heptyl (DMH) group, were tested on: (a) VR1-mediated increase in cytosolic Ca(2+) concentrations in cells over-expressing human VR1; (b) [(14)C]-AEA uptake by RBL-2H3 cells, which is facilitated by a selective membrane transporter; and (c) [(14)C]-AEA hydrolysis by rat brain membranes, which is catalysed by the fatty acid amide hydrolase. 3. Both CBD and (+)-CBD, but not the other analogues, stimulated VR1 with EC(50)=3.2 - 3.5 microM, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 - 70% of the effect obtained with ionomycin (4 microM). CBD (10 microM) desensitized VR1 to the action of capsaicin...Continue Reading

Associated Clinical Trials

References

May 29, 1992·Journal of Medicinal Chemistry·W A DevaneR Mechoulam
Jan 1, 1987·Journal of Cardiovascular Pharmacology·P BerntssonC Westerlund
Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·P J LittleB R Martin
Sep 1, 1989·Biochemical Pharmacology·L M Bornheim, M A Correia
Sep 15, 1988·Experientia·R MechoulamP Consroe
Dec 1, 1963·Tetrahedron·R Mechoulam, Y Shvo
Aug 1, 1981·Journal of Clinical Pharmacology·P ConsroeV Singh
Jan 1, 1994·General Pharmacology·F S GuimarãesA Breuer
Aug 1, 1996·Biological & Pharmaceutical Bulletin·K WatanabeH Yoshimura
Feb 7, 1997·The Journal of Biological Chemistry·T BisognoV Di Marzo
Jan 1, 1997·Pharmacology & Therapeutics·R G Pertwee
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·A J HampsonD Wink
Nov 4, 1998·FEBS Letters·V Di MarzoL De Petrocellis
Jun 1, 1999·Blood Cells, Molecules & Diseases·K N RithidechV P Bond
Aug 26, 1999·Life Sciences·A D Khanolkar, A Makriyannis
Nov 27, 1999·Forschende Komplementärmedizin·R Mechoulam
Feb 29, 2000·British Journal of Pharmacology·D SmartJ B Davis
Apr 29, 2000·Prostaglandins & Other Lipid Mediators·V Di MarzoT Bisogno
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·A M MalfaitM Feldmann
Aug 10, 2000·Proceedings of the National Academy of Sciences of the United States of America·S E Straus
Sep 28, 2000·Trends in Neurosciences·A Szallasi, V Di Marzo
Oct 13, 2000·Organic Letters·S Tchilibon, R Mechoulam
Oct 21, 2000·European Journal of Pharmacology·V Di MarzoB R Martin
Dec 7, 2000·Chemistry and Physics of Lipids·N UedaD G Deutsch
Dec 7, 2000·Chemistry and Physics of Lipids·C J Hillard, A Jarrahian
Jun 16, 2001·European Journal of Pharmacology·V Di MarzoJ J Fernandez-Ruiz

❮ Previous
Next ❯

Citations

Feb 21, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Markus KathmannEberhard Schlicker
Mar 31, 2006·Psychopharmacology·S A VarvelB R Martin
Jun 17, 2009·Psychopharmacology·Dagmar KoetheF Markus Leweke
Nov 16, 2011·Psychopharmacology·Maha M ElBatshD A Kendall
Jul 2, 2009·European Archives of Psychiatry and Clinical Neuroscience·Didier Jutras-AswadYasmin L Hurd
Feb 19, 2009·European Archives of Psychiatry and Clinical Neuroscience·Patrik RoserAndreas M Stadelmann
Jan 27, 2007·Molecular Genetics and Genomics : MGG·J M McPartlandC William Kilpatrick
Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Thomas W Klein, Guy A Cabral
Oct 23, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Luciano De Petrocellis, Vincenzo Di Marzo
Oct 24, 2007·Molecular Neurobiology·Stephen Wright
Oct 22, 2013·European Journal of Pharmacology·Mohamed MahgoubMurat Oz
Oct 9, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Felipe V GomesCarlos C Crestani
Sep 3, 2013·Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)·Amr A FouadWafaey Gomaa
Aug 9, 2013·Neuropharmacology·Francisco Espejo-PorrasConcepción García
Dec 31, 2002·Chemistry and Physics of Lipids·George KunosJudith Harvey-White
Nov 27, 2002·European Journal of Pharmacology·Roger G PertweeAdèle Thomas
Jul 10, 2003·Lancet Neurology·Arpad Szallasi, Clare J Fowler
Jan 19, 2011·ACS Chemical Neuroscience·Félix Viana
Sep 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Andrés Uribe-MariñoNorberto Cysne Coimbra
May 3, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Cristina A J SternLeandro J Bertoglio
Sep 2, 2004·Nature Reviews. Drug Discovery·Vincenzo Di MarzoLuciano De Petrocellis
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid A Taylor
Apr 9, 2008·The Journal of Biological Chemistry·Hamish Redmond RossMark Connor
Aug 19, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ali AltinsoyZeynep Sevim Ercan
Jan 11, 2005·Neuroreport·Kazuhide HayakawaMichihiro Fujiwara
Aug 10, 2010·Behavioural Pharmacology·Plinio C CasarottoFrancisco S Guimarães
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Alline Cristina CamposFrancisco Silveira Guimarães
Nov 13, 2009·The Journal of Pharmacology and Experimental Therapeutics·Nicholas A JonesGary J Stephens
Feb 18, 2010·The Journal of Pharmacology and Experimental Therapeutics·Keun-Hang YangMurat Oz
Sep 14, 2006·Pharmacological Reviews·Pál PacherGeorge Kunos
Aug 4, 2006·The Journal of Clinical Investigation·Haibin WangSudhansu K Dey
Aug 6, 2008·Pediatric Research·Francisco J AlvarezJosé Martínez-Orgado

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Psychopharmacology
Francisco Silveira GuimarãesAntonio Waldo Zuardi
Proceedings of the National Academy of Sciences of the United States of America
Erica J CarrierCecilia J Hillard
Progress in Neuro-psychopharmacology & Biological Psychiatry
F A MoreiraFrancisco Silveira Guimarães
Proceedings of the National Academy of Sciences of the United States of America
A M MalfaitM Feldmann
© 2021 Meta ULC. All rights reserved